Adverum Biotechnologies (ADVM)

Adverum Biotechnologies (ADVM) Income Statement


Adverum Biotechnologies Income Statement

Last quarter (Q1 2023), Adverum Biotechnologies's total revenue was $3.60M, an increase of Infinity% from the same quarter last year. In Q1, Adverum Biotechnologies's net income was $-28.32M. See Adverum Biotechnologies’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 3.60M-$ 7.50M$ 0.00$ 250.00K$ 1.61M
Cost of Revenue
Gross Profit
$ 7.70M-----
Operating Expense
$ 84.96M$ -157.13M$ 153.62M$ 117.95M$ 68.80M$ 74.69M
Operating Income
$ -149.24M$ -157.13M$ -146.12M$ -117.95M$ -68.55M$ -73.08M
Net Non Operating Interest Income Expense
$ 2.42M$ 2.67M----
Other Income Expense
$ 66.00K$ 788.00K$ 582.00K$ 1.56M$ 4.06M$ -796.00K
Pretax Income
$ -145.61M$ -154.46M$ -145.54M$ -116.39M$ -64.49M$ -73.88M
Tax Provision
$ 72.00K$ 74.00K$ 0.00$ 1.11M$ 0.00$ -1.25M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -144.54M$ -155.32M$ -145.54M$ -117.51M$ -64.49M$ -72.63M
Basic EPS
$ -1.47$ -1.56$ -1.48$ -1.38$ -1.01$ -1.18
Diluted EPS
$ -1.47$ -1.56$ -1.48$ -1.38$ -1.01$ -1.18
Basic Average Shares
$ 398.03M$ 99.25M$ 98.04M$ 85.15M$ 64.10M$ 61.38M
Diluted Average Shares
$ 398.03M$ 99.25M$ 98.04M$ 85.15M$ 64.10M$ 61.38M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 84.96M$ -157.13M$ 153.62M$ 117.95M$ 68.80M$ 74.69M
Net Income From Continuing And Discontinued Operation
$ -145.28M$ -155.32M$ -145.54M$ -117.51M$ -64.49M$ -72.63M
Normalized Income
$ -83.89M-$ -145.54M$ -117.51M$ -64.49M$ -67.71M
Interest Expense
$ -149.24M$ -157.13M$ -146.12M$ -117.95M$ -68.55M$ -73.08M
$ -142.68M$ -151.49M$ -141.48M$ -113.79M$ -66.97M$ -71.33M
Currency in USD

Adverum Biotechnologies Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis